Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1494-1497

  Rose, Peter G ^a   Fusco, Nancy ^a   Fluellen, Lisa ^a   Rodriguez, Michael ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NEUROPATHY; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SEPSIS; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA;

EID: 0031897980     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1494     Document Type: Article

References (22)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
2. Ransom DT, Patel SR, Keeney GL, et al: Papillary serous carcinoma of the peritoneum: A review of 33 cases treated with platin-based chemotherapy, Cancer 66:1091-1094, 1990
3. Wall JE, Mandrell BN, Jenkins JJ, et al: Effectiveness of paclitaxel in treating papillary serous carcinoma of the peritoneum in an adolescent. Am J Obstet Gynecol 172:1049-1052, 1995
4. Menzin AW, Aikins JK, Wheeler JE, et al: Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. Gynecol Oncol 62:55-58, 1996
5. Seltzer V, Vogl S, Kaplan B: Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cisdiamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 21:167-176, 1985
6. Gershenson DM, Kavanagh JJ, Copeland LJ, et al: Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 73:798-801, 1989
7. Gore ME, Fryatt I, Wiltshaw E, et al: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211, 1990
8. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
9. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
10. Rustin GJS, Nelstrop AE, McLean P, et al: Denning response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545-1551, 1996
11. Neijt JP: New therapy for ovarian cancer. N Engl J Med 334:50-51, 1996 (editorial)
12. Sutton GP, Stehman FB, Einhorn LH, et al: Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223-229, 1989
13. Markman M, Hoskins W: Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 10:513-514, 1992
14. Goldberg JM, Piver MS, Hempling RE, et al: Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 63:312-317, 1996
15. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
16. Rose PG, Blessing JA, Mayer AR, et al: Prolonged oral etoposide as second line therapy for platinum resistant (PLATR) and platinum sensitive (PLATS) ovarian carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 15:282, 1996 (abstr)
17. Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II trial. J Clin Oncol 14:3056-3061, 1996
18. Colombo N, Marzola M, Parma G, et al: Paclitaxel vs CAP (cyclophosphamide, Adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: A randomized phase II study. Proc Am Soc Clin Oncol 15:279, 1996 (abstr)
19. Parker RJ, Dabholkar MD, Lee KB, et al: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Monogr Natl Cancer Inst 15:83-88, 1993
20. Johnston CM, Pearl ML, Reynolds RK, et al: Treatment of refractory ovarian carcinoma with paclitaxel and cisplatinum after treatment failure with single agent paclitaxel. Eur J Gynecol Oncol 16:439-447, 1995
21. Bokkel Huinink WT, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
22. Markman M, Kennedy A, Webster K, et al: Continued chemosensitivity to cisplatin/carboplatin in ovarian cancer despite treatment with multiple prior platinum-based regimens. Gynecol Oncol 65:434-436, 1997